Cooper Investors PTY Ltd. Boosts Stake in Stevanato Group S.p.A. $STVN

Cooper Investors PTY Ltd. increased its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 4.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 668,494 shares of the company’s stock after purchasing an additional 28,265 shares during the period. Stevanato Group makes up 5.5% of Cooper Investors PTY Ltd.’s portfolio, making the stock its 4th biggest position. Cooper Investors PTY Ltd.’s holdings in Stevanato Group were worth $12,080,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in STVN. Confluence Investment Management LLC acquired a new stake in Stevanato Group during the second quarter valued at approximately $6,062,000. Glenmede Trust Co. NA raised its holdings in shares of Stevanato Group by 29.5% in the 1st quarter. Glenmede Trust Co. NA now owns 38,461 shares of the company’s stock worth $529,000 after buying an additional 8,770 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Stevanato Group by 15.8% in the 1st quarter. Royal Bank of Canada now owns 421,696 shares of the company’s stock worth $5,798,000 after buying an additional 57,536 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of Stevanato Group during the 1st quarter worth approximately $1,749,000. Finally, Sei Investments Co. lifted its position in shares of Stevanato Group by 4.0% during the 1st quarter. Sei Investments Co. now owns 266,218 shares of the company’s stock worth $3,661,000 after buying an additional 10,203 shares during the period.

Insider Buying and Selling at Stevanato Group

In related news, Director Karen Flynn sold 1,493 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of €17.09, for a total transaction of €25,515.37. Following the sale, the director owned 5,757 shares in the company, valued at approximately €98,387.13. This represents a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Donald E. Morel, Jr. sold 1,493 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of €17.09, for a total value of €25,515.37. Following the transaction, the director directly owned 37,424 shares in the company, valued at €639,576.16. This trade represents a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 5,972 shares of company stock valued at $102,061.

Wall Street Analyst Weigh In

STVN has been the topic of several recent analyst reports. Weiss Ratings raised Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 16th. TD Cowen raised shares of Stevanato Group to a “strong-buy” rating in a report on Wednesday, June 17th. Finally, Wolfe Research assumed coverage on Stevanato Group in a report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

Key Stories Impacting Stevanato Group

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Stevanato reported second-quarter revenue of €302.0 million, an 8% year-over-year increase. High-value solutions accounted for 45% of revenue, and gross profit margin improved, indicating continued demand for the company’s drug-containment, drug-delivery and diagnostic products. Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
• Positive Sentiment: Management raised or reaffirmed a favorable 2026 outlook, calling for EPS of $0.700-$0.720 versus analyst expectations of $0.680. Revenue guidance was approximately $1.5 billion, broadly in line with consensus, suggesting profitability is expected to outperform despite modest top-line expectations.
• Positive Sentiment: The company is targeting €335 million to €345.2 million in adjusted EBITDA for 2026 following the divestiture of Balda C. Brewer. The target gives investors a clearer view of expected profitability after the portfolio change. Stevanato targets adjusted EBITDA following Balda C. Brewer divestiture
• Neutral Sentiment: The earnings-call coverage focused on the company’s second-quarter performance, updated guidance and strategy following the divestiture. Investors are likely looking for further detail on demand trends, margins and the pace of growth during the call. Stevanato Group Q2 2026 Earnings Call Transcript
• Negative Sentiment: Reported quarterly EPS was mixed: one report cited €0.14 versus a €0.15 consensus estimate, while another cited $0.16 versus a $0.15 estimate. The conflicting figures may be creating uncertainty, but the reported miss in the company’s local-currency presentation could be weighing on the stock despite the stronger guidance.

Stevanato Group Trading Up 0.6%

NYSE STVN opened at €19.78 on Wednesday. The stock has a market capitalization of $5.99 billion, a price-to-earnings ratio of 33.52, a PEG ratio of 1.84 and a beta of 0.77. Stevanato Group S.p.A. has a 52 week low of €12.89 and a 52 week high of €28.00. The stock’s 50 day moving average price is €18.70 and its two-hundred day moving average price is €16.97. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The business had revenue of €273.57 million during the quarter. Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The firm’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. As a group, analysts anticipate that Stevanato Group S.p.A. will post 0.71 earnings per share for the current fiscal year.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.